Nuvation Bio (NUVB) Cash & Equivalents (2020 - 2026)

Nuvation Bio (NUVB) has reported Cash & Equivalents for 7 consecutive years, with $125.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 161.36% year-over-year to $125.4 million; the TTM figure through Mar 2026 stood at $125.4 million (up 161.36% YoY), while the FY2025 annual figure was $164.1 million, up 359.33% from the prior year.
• Cash & Equivalents declined to $125.4 million in Q1 2026 per NUVB's latest filing, from $164.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $248.0 million in Q2 2025 and bottomed at $24.4 million in Q3 2023.
• Historically, Cash & Equivalents has averaged $83.2 million across 5 years, with a median of $50.1 million in 2023.
• Annual changes were most pronounced in 2022 — Cash & Equivalents slumped 83.38% — and 2025, when it jumped 623.26%.
• Nuvation Bio's Cash & Equivalents stood at $101.1 million in 2022, then slumped by 57.81% to $42.6 million in 2023, then declined by 16.24% to $35.7 million in 2024, then soared by 359.33% to $164.1 million in 2025, then retreated by 23.58% to $125.4 million in 2026.
• Business Quant data shows NUVB's Cash & Equivalents at $125.4 million in Q1 2026, $164.1 million in Q4 2025, and $98.9 million in Q3 2025.